Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$13.81 USD
+1.32 (10.57%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.00 +0.19 (1.38%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EBS 13.81 +1.32(10.57%)
Will EBS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EBS
Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?
Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound?
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Other News for EBS
Emergent BioSolutions launches opioid emergency prepardness campaign
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in Canada
Emergent BioSolutions announces shelf-life extension for NARCAN spray in Canada